NO964808L - Interleukin-5 spesifikke rekombinante antistoffer - Google Patents

Interleukin-5 spesifikke rekombinante antistoffer

Info

Publication number
NO964808L
NO964808L NO964808A NO964808A NO964808L NO 964808 L NO964808 L NO 964808L NO 964808 A NO964808 A NO 964808A NO 964808 A NO964808 A NO 964808A NO 964808 L NO964808 L NO 964808L
Authority
NO
Norway
Prior art keywords
interleukin
recombinant antibodies
specific recombinant
specific
heavy
Prior art date
Application number
NO964808A
Other languages
English (en)
Norwegian (no)
Other versions
NO964808D0 (no
Inventor
John Spencer Emtage
Mark William Bodmer
Diljeet Singh Athwal
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Publication of NO964808D0 publication Critical patent/NO964808D0/no
Publication of NO964808L publication Critical patent/NO964808L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO964808A 1994-06-17 1996-11-13 Interleukin-5 spesifikke rekombinante antistoffer NO964808L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412230A GB9412230D0 (en) 1994-06-17 1994-06-17 Interleukin-5 specific recombiant antibodies
PCT/GB1995/001411 WO1995035375A1 (en) 1994-06-17 1995-06-16 Interleukin-5 specific recombinant antibodies

Publications (2)

Publication Number Publication Date
NO964808D0 NO964808D0 (no) 1996-11-13
NO964808L true NO964808L (no) 1997-02-17

Family

ID=10756925

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964808A NO964808L (no) 1994-06-17 1996-11-13 Interleukin-5 spesifikke rekombinante antistoffer

Country Status (18)

Country Link
US (3) US5998586A (de)
EP (1) EP0765392B1 (de)
JP (1) JP3973682B2 (de)
AT (1) ATE264389T1 (de)
AU (1) AU694783B2 (de)
CA (1) CA2192543C (de)
CZ (1) CZ292295B6 (de)
DE (1) DE69532889T2 (de)
ES (1) ES2218546T3 (de)
FI (1) FI965032L (de)
GB (1) GB9412230D0 (de)
HU (1) HU221641B1 (de)
IL (1) IL114179A (de)
NO (1) NO964808L (de)
NZ (1) NZ287927A (de)
SK (1) SK282625B6 (de)
WO (1) WO1995035375A1 (de)
ZA (1) ZA954990B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39548E1 (en) 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
CA2208503C (en) * 1994-12-23 2009-12-01 Smithkline Beecham P.L.C. Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
HUP0200958A3 (en) 1999-04-23 2004-11-29 Pharmexa As Method for down-regulating il5 activity
TWI422387B (zh) 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
JP5917143B2 (ja) 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
EP3130607B1 (de) * 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1*-antikörper
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (de) 2010-10-01 2018-06-27 ModernaTX, Inc. Manipulierte nukleinsäuren und anwendungsverfahren dafür
US9505826B2 (en) * 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
WO2014105910A1 (en) 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
CN106794194A (zh) 2014-06-30 2017-05-31 中央研究院 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
KR20180037275A (ko) 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
BR112019025736A2 (pt) 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
US11365247B2 (en) 2017-09-29 2022-06-21 Jiangsu Hengrui Medicine Co., Ltd. IL-5 antibody, antigen binding fragment thereof, and medical application therefor
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US20220010008A1 (en) * 2018-12-12 2022-01-13 Shanghai Pharmaexplorer Co., Ltd. Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
AU2020251627A1 (en) 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU633034B2 (en) * 1988-11-03 1993-01-21 Schering Corporation Method of preventing or reducing eosinophilia
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
HUT67943A (en) * 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
CA2130436C (en) * 1992-02-19 2001-04-10 John S. Abrams Cloning and expression of humanized monoclonal antibodies against human interleukin-4
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies

Also Published As

Publication number Publication date
SK282625B6 (sk) 2002-10-08
FI965032A7 (fi) 1996-12-16
ZA954990B (en) 1996-12-17
AU2680395A (en) 1996-01-15
FI965032A0 (fi) 1996-12-16
ATE264389T1 (de) 2004-04-15
HU221641B1 (hu) 2002-12-28
HUT76672A (en) 1997-10-28
CZ371296A3 (cs) 1998-05-13
JP3973682B2 (ja) 2007-09-12
NZ287927A (en) 1998-07-28
EP0765392A1 (de) 1997-04-02
HU9603183D0 (en) 1997-01-28
CA2192543A1 (en) 1995-12-28
WO1995035375A1 (en) 1995-12-28
SK160096A3 (en) 1997-06-04
AU694783B2 (en) 1998-07-30
US6734286B2 (en) 2004-05-11
IL114179A0 (en) 1995-10-31
CA2192543C (en) 2008-07-29
DE69532889D1 (de) 2004-05-19
JPH10501697A (ja) 1998-02-17
US20020042089A1 (en) 2002-04-11
GB9412230D0 (en) 1994-08-10
EP0765392B1 (de) 2004-04-14
US5998586A (en) 1999-12-07
IL114179A (en) 2001-08-26
US6316227B1 (en) 2001-11-13
FI965032L (fi) 1996-12-16
CZ292295B6 (cs) 2003-08-13
NO964808D0 (no) 1996-11-13
DE69532889T2 (de) 2005-03-10
ES2218546T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
ATE264389T1 (de) Interleukin-5-spezifische rekombinante antikörper
FI956112A0 (fi) Monoklonaalinen anti- V-integriinivasta-aine
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
DE68914244D1 (de) Monoklonaler Antikörper.
FI960567L (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
FI945865L (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE69738312D1 (de) Hepatitis b monoklonale antikörper
TR199800517A3 (tr) Hümanize anti-hümen fas antikor.
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
NO890116L (no) Monoklonale antistoffer.
FI934963A7 (fi) CTAA 81AV78, monoklonaalisen 81AV78-humaanivasta-aineen tunnistama ant igeeni
DE69023717D1 (de) Monoklonaler Antikörper.
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.
ITRM920223A0 (it) Anticorpi monoclonali anti-idiopici diretti contro anticorpi anti-tnf.
NO960683L (no) Monoklonalt antistoff som gjenkjenner interstitialcelle-overflateantigen
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
FI925638A7 (fi) Kasvainten yhteydessä esiintyvää antigeenia vastaan suunnattu monoklonaalinen vasta-aine 88BV59
DE69324928D1 (de) Monoklonaler antikörper
DE68916088D1 (de) Anti-CPBII-monoklonaler Antikörper.
FI935038A7 (fi) Kasvaimiin liittyvä monoklonaalinen vasta-aine 81AV78
NO903788D0 (no) Monoklonalt antistoff mot protein c.
DE69320192D1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast